Brokerages Set Repligen Co. (NASDAQ:RGEN) Target Price at $197.75

Shares of Repligen Co. (NASDAQ:RGEN) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $193.00.

A number of equities analysts have recently weighed in on the company. Guggenheim started coverage on Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating on the stock. JPMorgan Chase & Co. dropped their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Finally, Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th.

Insiders Place Their Bets

In other news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Martin D. Madaus bought 1,615 shares of Repligen stock in a transaction on Friday, June 14th. The shares were purchased at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the acquisition, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently added to or reduced their stakes in the company. YHB Investment Advisors Inc. purchased a new position in Repligen during the 1st quarter valued at about $26,000. Lazard Asset Management LLC boosted its position in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the last quarter. Principal Securities Inc. bought a new position in Repligen during the 4th quarter valued at approximately $48,000. Finally, CWM LLC raised its stake in Repligen by 19.9% during the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN opened at $126.06 on Wednesday. The company has a market cap of $7.04 billion, a price-to-earnings ratio of 504.26, a PEG ratio of 4.21 and a beta of 1.04. The company’s fifty day moving average price is $151.71 and its two-hundred day moving average price is $173.93. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. During the same period in the previous year, the company posted $0.64 earnings per share. The company’s quarterly revenue was down 17.1% compared to the same quarter last year. On average, analysts expect that Repligen will post 1.46 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.